Teva Pharmaceutical Industries Reports Strong AUSTEDO Growth and Announces $700M Emalex Acquisition
Teva Pharmaceutical Industries reported first-quarter revenue of $4 billion, with a 1% decline year-over-year but strong performance in its innovative portfolio led by the drug AUSTEDO. The company also announced plans to acquire Emalex for up to $900 million to gain access to ecopipam for Tourette syndrome.
Tickers: $TEVA
Topics: acquisitions innovative_portfolio_growth pharmaceuticals